Abstracts tagged "Oncology"

Abstract Number: 0460 • ACR Convergence 2025
The Impact of Early and Artificial Menopause on Dementia Risk Among Women with Rheumatoid Arthritis
Ryan Salama¹, Cassondra Hulshizer², Cynthia Crowson³ and Elena myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Alzheimer’s disease and related dementias present an increasing global health concern, with increasing incidence and prevalence. Hormonal fluctuations associated with menopause may exacerbate inflammatory…
Abstract Number: 1920 • ACR Convergence 2025
Lung Cancer Screening with Rheumatoid Arthritis: A Retrospective Claims Analysis
Angeles Lopez-Olivio¹, Zhigang Duan², Huifang Lu³, Edwin J. Ostrin², Robert J. Volk², Ying Xu², Sharon H. Giordano⁴ and Hui Zhao⁴, ¹The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³UT MD Anderson Cancer Center, Houston, TX, ⁴The University of Texas MD Anderson Cancer Center, Houston
Background/Purpose: Patients with rheumatoid arthritis (RA) are at elevated risk for lung cancer. Lung cancer screening (LCS) with low-dose computed tomography (LDCT) is recommended for…
Abstract Number: 0457 • ACR Convergence 2025
Pulmonary Profiles: Characterizing Lung Findings in Rheumatoid Arthritis Patients Undergoing Lung Cancer Screening
Pratyusha Banik¹, Melody Andrews¹, Sudhakar Pipavath¹ and Namrata Singh², ¹University of Washington, Seattle, WA, ²University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid arthritis (RA) has been associated with an increased risk of lung cancer with shared risk factors being heavy smoking history and possibly interstitial…
Abstract Number: 1730 • ACR Convergence 2025
Oral glucocorticoid treatment for checkpoint inhibitor associated inflammatory arthritis do not affect progression free survival: a RADIOS Registry cohort study
Deanna Jannat-Khah¹, Pankti Reid², Maria Suarez-Almazor³, Noha Abdel-Wahab⁴, Jeffrey Sparks⁵, Tawnie Braaten⁶, Cassandra Calabrese⁷, Alexa Meara⁸, Minerva Nong⁹, Kyle Ge¹⁰, Laura Cappelli¹¹, Ami Shah¹², Clifton Bingham¹³ and Anne R. Bass¹, ¹Hospital For Special Surgery, New York, NY, ²University of Chicago Medical Center, Chicago, IL, ³MD Anderson Cancer Center, Houston, TX, ⁴University of Texas MD Anderson Cancer Center, houston, TX, ⁵Brigham and Women's Hospital, Boston, MA, ⁶UNIVERSITY OF UTAH, Salt Lake City, UT, ⁷Cleveland Clinic Foundation, Cleveland Heights, OH, ⁸The Ohio State University Wexner Medical Center, COLUMBUS, OH, ⁹Columbia University, New York, ¹⁰Hospital for Special Surgery, New York, ¹¹Johns Hopkins School of Medicine, Baltimore, MD, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³Johns Hopkins University, Baltimore, MD
Background/Purpose: As immune checkpoint inhibitor (ICI) usage increases for various cancers the prevalence of rheumatologic immune related adverse events (irAEs) also grows. Glucocorticoids are first…
Abstract Number: 0300 • ACR Convergence 2025
Exploring Malignancy in Anti-synthetase Syndrome: A Multisite Retrospective Study
Reena Yaman¹, Archit Srivastava², Alejandro Arango Martinez³, Caroyln Harvey⁴, Ronald Butendieck⁵, Vikas Majithia⁶ and Florentina Berianu¹, ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic, Florida, Jacksonville, FL, ³Universidad Pontificia Bolivariana, Medellín, Colombia, ⁴Mayo Clinic, Phoenix, AZ, ⁵Mayo Clinic Florida, Jacksonville, ⁶Mayo Clinic Hospital, Jacksonville, FL
Background/Purpose: Anti-synthetase syndrome (ASyS) is a rare, heterogeneous inflammatory myopathy characterized by presence of anti-aminoacyl transfer RNA synthetase autoantibodies with multisystem disease manifestations including myositis,…
Abstract Number: 1731 • ACR Convergence 2025
A Post-Marketing Analysis of Autoimmune Toxicities Following Chimeric Antigen Receptor T-Cell Therapy Using the FDA Adverse Event Reporting System
Malvika Gupta¹, Christopher Graham² and Supriya Gupta³, ¹Mayo Clinic, Rochester MN, Rochester, MN, ²University of Minnesota, Minneapoils, MN, ³University of Minnesota, Minneapolis, MN
Background/Purpose: Chimeric Antigen Receptor (CAR-T) therapy has transformed the management of hematologic cancers, with multiple products approved by the U.S. Food and Drug Administration (FDA).…
Abstract Number: 0209 • ACR Convergence 2025
A Retrospective Safety Analysis based on Platelets in Arthrocentesis and Joint injections in Cancer Patients
Yuanteng Li¹, Cheuk Leung², Heather Lin², Angeles Lopez-Olivio³ and Jean Tayar³, ¹MD Anderson Cancer Center, Houston, TX, ²MD Anderson Cancer Center, Houston, ³The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Arthrocentesis and joint injections are commonly performed to diagnose and to treat rheumatic conditions such as crystal-induced arthritis, septic arthritis, and inflammatory arthritis. While…
Abstract Number: 1729 • ACR Convergence 2025
The ERIN Registry: Real-World Data on Rheumatic Immune-Related Adverse Events from Immune Checkpoint Inhibitor Therapy
Didzis Gailis¹, Fabian T.H. Ullrich¹, Sophia Dombret¹, Rebecca Hasseli-Fräbel², Marc Schmalzing³, Torsten Witte⁴, Mara Oleszowsky⁵, Marcel Müller⁶, Karolina Gente⁷, Uta Kiltz⁸, Christof Specker⁹, Alla Skapenko¹⁰ and Hendrik Schulze-Koops¹⁰, ¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, LMU University Hospital, Münich, Bayern, Germany, ²Section of Rheumatology and Clinical Immunology, University Hospital Munster, Münster, Nordrhein-Westfalen, Germany, ³Department of Medicine II, Rheumatology/ Immunology,University Hospital of Wuerzburg, Wuerzburg, Bayern, Germany, ⁴Dept of Rheumatology and Immunology, Hannover, Niedersachsen, Germany, ⁵Private Rheumatology Practice, Köln, Nordrhein-Westfalen, Germany, ⁶The Institute for Medical Information Processing, Biometry, and Epidemiology, LMU University Hospital, München, Bayern, Germany, ⁷Department of Internal Medicine V - Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Baden-Wurttemberg, Germany, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁹Department of Rheumatology and Clinical Immunology, Kliniken Essen-Mitte, Düsseldorf, Nordrhein-Westfalen, Germany, ¹⁰LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany
Background/Purpose: Immune checkpoint inhibitors (ICIs) are a mainstay of cancer immunotherapy. However, their increasing use has led to more immune-related adverse events (irAEs), including rheumatic…
Abstract Number: 0172 • ACR Convergence 2025
Cancer Screening for Patients with Rheumatic Diseases: A Scoping Review
Teresa Xiao¹, Namrata Singh² and Pankti Reid³, ¹University of Chicago, Chicago, IL, ²University of Washington, Bellevue, WA, ³University of Chicago Medical Center, Chicago, IL
Background/Purpose: There is minimal guidance on specific cancer screening practices for rheumatic diseases (RDs) other than for myositis. The aim of this scoping review was…
Abstract Number: 1492 • ACR Convergence 2025
Prevalence and Risk Factors of Gynecologic Cancers in Female Patients with Systemic Lupus Erythematosus
Katherine Moseley¹, Dulaney Wilson², Emily Vara¹ and Diane Kamen³, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³Medical University of South Carolina, Johns Island, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic systemic autoimmune disorder that is nine times more prevalent in women. Patients with SLE are at an…
Abstract Number: 0145 • ACR Convergence 2025
Population Assessment of Cancer Incidence among Patients with Idiopathic Inflammatory Myopathies in North Carolina
Astia Allenzara¹, Ben Albright², Xi Zhou², Amanda Nelson³, Laura Green⁴, Katherine Reeder-Hayes⁴, Jennifer Lund⁴, Caroline Thompson⁴ and Chris Baggett⁴, ¹UNC, Chapel Hill, NC, ²University of North Carolina, Chapel Hill, NC, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴University of North Carolina, Chapel Hill
Background/Purpose: Cancer is highly prevalent and a leading cause of death for patients with Idiopathic Inflammatory Myopathies (IIM). Evaluating cancer type and stage at diagnosis…
Abstract Number: 1386 • ACR Convergence 2025
Characterization and Progression of Localized Amyloidosis in Sjogren’s Syndrome: Evidence Long-Term (1995-2025) Follow-Up of a Cohort compared to Literature Review.
Hoang Nguyen¹, Philip Moresco², Antoine Chiu², Asha Patnaik³ and Peter Gorevic⁴, ¹Stony Brook University-Renaissance School of Medicine- Department of Rheumatology, Jamaica, NY, ²Stony Brook University -Renaissance School of Medicine, Stony Brook, NY, ³Stony Brook University Hospital, Stony Brook, NY, ⁴Stony Brook University, Stony Brook, NY
Background/Purpose: -Sjogren’s syndrome (SS) is a chronic autoimmune disorder, defined by keratoconjunctivitis sicca (KCS), specific serologies, and a significant risk of extra-exocrine disease manifestations and…
Abstract Number: 1351 • ACR Convergence 2025
Are Glucocorticoids Associated with Worse Overall Survival among Rheumatoid Arthritis Patients Treated with Immune Checkpoint Inhibitors? The Confounding Effect of Dexamethasone
Deanna Jannat-Khah¹, Jeffrey Curtis², Fenglong Xie³, Ashish Saxena⁴ and Anne R. Bass¹, ¹Hospital For Special Surgery, New York, NY, ²Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, New York
Background/Purpose: Previous studies suggest that glucocorticoids are associated with worse survival in patients receiving immune checkpoint inhibitors (ICI). This is an important issue for Rheumatoid…
Abstract Number: 1117 • ACR Convergence 2025
Inflammatory Arthritis after Hematopoietic Stem Cell Transplant: A Case Series and Literature Review
Scott Yeudall¹, Mark Levis², Jonathan Webster² and Laura Cappelli³, ¹The Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Hematopoietic stem cell transplant (HSCT) is a commonly employed treatment for hematologic malignancies including acute leukemias and lymphomas but can be complicated by graft-versus-host…
Abstract Number: 0989 • ACR Convergence 2024
Malignancy Risk Between JAK Inhibitors and Anti-TNF Therapy Across Disease Indications: A Bayesian Network Meta-analysis
Mark Gibson¹, Benjamin Zuckerman², Maryam Adas¹, Mark Russell³, Katie Bechman¹ and James Galloway⁴, ¹King's College London, London, United Kingdom, ²King's College London, London, England, United Kingdom, ³King's College London, London, United Kingdom, ⁴Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: To estimate the relative risk of malignancy between Janus kinase inhibitors (JAKi), tumour necrosis factor-α inhibitors (TNFi) and placebo in individuals with immune-mediated inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].